All News

27 February 2025

Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02Antibodies

27 February 2025

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary AngioedemaAntibodies

26 February 2025

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and CompanyMore News

26 February 2025

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trialSmall Molecules

26 February 2025

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaAntibodies

26 February 2025

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of ObesityDNA RNA and Cells

26 February 2025

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha InhibitorSmall Molecules

26 February 2025

SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine CandidateVaccines

26 February 2025

FDA Grants Priority Review to Precigen’s BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025DNA RNA and Cells

26 February 2025

HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine TherapiesAntibodies

26 February 2025

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority ReviewAntibodies

26 February 2025

Inceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 FinancingDNA RNA and Cells

26 February 2025

BridGene Biosciences Announces Strategic Collaboration with Takeda to Discover Small Molecule Drugs for Immunology and Neurology TargetsMore News

26 February 2025

Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple MyelomaSmall Molecules

25 February 2025

CancerVax Announces Successful Tests of its Smart mRNA TechnologyVaccines

25 February 2025

YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)DNA RNA and Cells

24 February 2025

Vicero’s Novel Cancer Immunotherapy Demonstrates Dual-Target Precision with Improved Safety ProfileAntibodies

24 February 2025

LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301Antibodies

24 February 2025

NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant PatientsAntibodies

24 February 2025

ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s DiseaseDNA RNA and Cells

24 February 2025

Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United StatesAntibodies

24 February 2025

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal CancerAntibodies

24 February 2025

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)Antibodies

24 February 2025

Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to StelaraAntibodies

24 February 2025

Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)Antibodies

24 February 2025

Halda Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating HLD-0915 in Metastatic Castration-Resistant Prostate CancerSmall Molecules

22 February 2025

Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosisDNA RNA and Cells

22 February 2025

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK CapitalMore News

22 February 2025

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose CohortDNA RNA and Cells

22 February 2025

Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary CholangitisSmall Molecules

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

2023 Sales of Antibodies & Proteins

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Report Package: Claudin 18.2-Targeted Immunotherapeutics

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CCR8-Targeted Antibody Immunotherapy Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective